Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N8RV
|
|||
| Former ID |
DCL000352
|
|||
| Drug Name |
OSI-930
|
|||
| Synonyms |
OSI 930; OSI930; OSI-930 is a multi-targeted tyrosine kinase inhibitor; 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
OSI Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H16F3N3O2S
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=CC=N2)CNC3=C(SC=C3)C(=O)NC4=CC=C(C=C4)OC(F)(F)F
|
|||
| InChI |
1S/C22H16F3N3O2S/c23-22(24,25)30-16-7-5-15(6-8-16)28-21(29)20-19(10-12-31-20)27-13-14-9-11-26-18-4-2-1-3-17(14)18/h1-12,27H,13H2,(H,28,29)
|
|||
| InChIKey |
FGTCROZDHDSNIO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 728033-96-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14832924, 24159478, 45290301, 50086917, 76827455, 99437032, 124757092, 125163896, 126671661, 131480731, 134339004, 135261678, 136367364, 136920358, 136933680, 136960901, 137276003, 142845297, 144116325, 152258120, 160646959, 162011684, 162037502, 162202664, 174530503, 177748914, 180386841, 186007038, 188899584, 198968760, 223679984, 223704833, 226933716, 242059898, 248747184, 251971154, 252160242, 252215971, 252451811
|
|||
| ChEBI ID |
CHEBI:91433
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74. | |||
| REF 2 | Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6495-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.